Evidence map›Paper›PMID 23614568›Full record

ArticleBiochemistry2013

Kinetic mechanism of human histidine triad nucleotide binding protein 1.

Xin Zhou, Tsui-Fen Chou, Brandon E Aubol, Chin Ju Park, Richard Wolfenden, Joseph Adams, Carston R Wagner

Abstract read
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Many Faces of Histidine Triad Nucleotide Binding Protein 1 (HINT1).ACS pharmacology & translational science · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Intracellular HINT1-Assisted Hydrolysis of Nucleoside 5'-International journal of molecular sciences · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Xin ZhouDepartment of Medicinal Chemistry and ‡Minnesota NMR Facility, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Tsui-Fen Chou
Brandon E Aubol
Chin Ju Park
Richard Wolfenden
Joseph Adams
Carston R Wagner
Twin Cities Orthopedics · USUniversity of California, San Diego · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
CHEMICAL MECHANISMS OF BIOSYNTHESISR01GM018325 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFENDEN, RICHARD VANCE · 1985 to 2011
$4.0M
CHEMICAL MECHANISMS OF BIOSYNTHESISR37GM018325 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI WOLFENDEN, RICHARD VANCE · 1990 to 1999
–
NIGMS NIH HHS GM-18325NIGMS NIH HHS R01 GM018325NIGMS NIH HHS R37 GM018325NIGMS NIH HHS T32 GM007752
6 · The paper itself

Abstract

Human histidine triad nucleotide binding protein 1 (hHint1) is a member of a ubiquitous and ancient branch of the histidine triad protein superfamily. hHint1 is a homodimeric protein that catalyzes the hydrolysis of model substrates, phosphoramidate and acyl adenylate, with a high efficiency. Recently, catalytically inactive hHint1 has been identified as the cause of inherited peripheral neuropathy [Zimon, M., et al. (2012) Nat. Genet. 44, 1080-1083]. We have conducted the first detailed kinetic mechanistic studies of hHint1 and have found that the reaction mechanism is consistent with a double-displacement mechanism, in which the active site nucleophile His112 is first adenylylated by the substrate, followed by hydrolysis of the AMP-enzyme intermediate. A transient burst phase followed by a linear phase from the stopped-flow fluorescence assay indicated that enzyme adenylylation was faster than the subsequent intermediate hydrolysis and product release. Solvent viscosity experiments suggested that both chemical transformation and diffusion-sensitive events (product release or protein conformational change) limit the overall turnover. The catalytic trapping experiments and data simulation indicated that the true koff rate of the final product AMP is unlikely to control the overall kcat. Therefore, a protein conformational change associated with product release is likely rate-limiting. In addition, the rate of Hint1 adenylylation was found to be dependent on two residues with pKa values of 6.5 and 8, with the former pKa agreeing well with the nuclear magnetic resonance titration results for the pKa of the active site nucleophile His112. In comparison to the uncatalyzed rates, hHint1 was shown to enhance acyl-AMP and AMP phosphoramidate hydrolysis by 10(6)-10(8)-fold. Taken together, our analysis indicates that hHint1 catalyzes the hydrolysis of phosphoramidate and acyl adenylate with high efficiency, through a mechanism that relies on rapid adenylylation of the active residue, His112, while being partially rate-limited by intermediate hydrolysis and product release associated with a conformational change. Given the high degree of sequence homology of Hint proteins across all kingdoms of life, it is likely that their kinetic and catalytic mechanisms will be similar to those elucidated for hHint1.

Indexed as

Binding SitesCatalysisHistidineHumansHydrogen-Ion ConcentrationKineticsNerve Tissue ProteinsHINT1 protein, humanHistidineNerve Tissue Proteins

Identifiers

PMID23614568
PMCPMC3835729
OpenAlexW2057834641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.